Page 56 - CIBERSAM-2015-eng

Research Groups
Group 12
Programme: Psychosomatic, Anxiety and Impulse Control Disorders / Therapeutic Innovation
Lead Researcher: Leza Cerro, Juan Carlos
Group Members
STAFF MEMBERS: Martín Hernández, David
ASSOCIATED MEMBERS: Carrasco Perera, José Luis | Díaz Marsa, Marina | García Bueno, Borja | Macdowell
Mata, Karina | Muñoz Madrigal, José Luis | Rodríguez Maus, Sandra | Sayd, Aline.
Main lines of research
• Search for inflammation biomarkers in plasma an blood cells from neuropsychiatric disease patients in order to identify and develop new therapeutic strategies.
• Study of protection mechanisms against oxidative and inflammatory cell damage after stress expo- sure. Identification of potential therapeutic targets and evaluation of neuroprotection strategies.
• Study of individual mechanisms of susceptibility to stress-induced cell damage.
• Study of mechanisms through which noradren- aline acts as an anti-inflammatory mediator in stress. Among them, the key role of the chemokine MCP-1.
• Study of stress-induced colonic bacteria translo- cation during brain response to stress.
• Elucidation of the mechanisms through which stress exposure increases susceptibility and cell damage in Alzheimer´s disease, Parkinson´s dis-
ease, brain hypoxia and demyelinating diseases models. Identification of potential therapeutic tar- gets and evaluation of neuroprotective strategies.
• Elucidation of the mechanisms through which stress exposure increases susceptibility and cell damage in the intestine. Identification of potential therapeutic targets and evaluation of cytoprotec- tive strategies.
• Evaluation of the therapeutic potential of the endo- cannabinoid system in neuropsychiatric and gas- trointestinal pathologies caused by stress.
• Potential new mechanisms: role of innate immuni- ty receptors (TLRs) in stress-related processes in neuro-psychiatric pathologies models.
• Study of the neuroprotective effects resultant from the administration of different types of antidepres- sant and antipsychotic drugs in animal models (in vivo and in vitro) of psychiatric diseases.
56 I Annual report 2015 I CIBERSAM